The Role of Venoactive Drugs in Venous Disorders [CME] (UIP2013-53)
This course will provide an overview of the impact and efficacy of venoactive drugs in venous disorders, and patients with venous edema. Discussions will include evidence of efficacy of micronized purified flavonoid fraction, edema and venoactive efficacy, and pharmacologic treatment in venous ulcer patients.
This course will include:
Steps to Successfully Complete This Activity
To participate in this educational activity please follow the steps listed below.
If you are new to the ACP Online Education Center we require that you register prior to viewing any activity. Click the Register link located in the top right corner of this screen to do so. If you are already a registered user log in and click the TAKE COURSE button that will appear in the Course Summary box.
- To begin the activity click the START COURSE button.
- Progress through course content by using the NEXT button.
- Complete all required items in the course.
- Participants must score 80% or greater on the Post-Test to advance and receive credit. They are given three attempts to meet this threshold.
- Track your progress using the Course Progress menu.
- On the final page of the activity a link will be provided to download your certificate.
The content of this activity is designed to meet the needs of the following target audience: phlebologists, general surgeons, vascular surgeons, interventional radiologists, interventional cardiologists, vascular medicine practitioners, dermatologists, dermatologic surgeons, family practice and internal medicine practitioners, plastic surgeons, obstetricians and gynecologists, cardiologists, and any other healthcare professional currently or planning on treating patients with venous disease.
As a result of this activity, the participant should be able to:
- Define the different classes of venoactive drugs.
- Define the mode of action and effectiveness of venoactive drugs in venous disorders.
- Choose correct and effective indications of venoactive drugs.
|NAME||ROLE||COMMERCIAL INTEREST||TYPE OF RELATIONSHIP|
|Francois–Andre Allaert, MD, PhD||Speaker||NONE|
|Philip Coleridge–Smith, MD, FRCS||Speaker||NONE|
|Emily Cummings, MD||Content Reviewer||NONE|
|Heather Durband, BS||Staff||NONE|
|Antonio Gasparis, MD||Scientific Committee/Planner||Covidien; Cook; Vascular Insights; Gore||Consultant/Speaker|
|Jean-Jérôme Guex, MD, FACPh||Scientific Committee/Planner||Servier International; Thuasne; Vascular Insights||Speaker/Consultant; Scientific Committee Member|
|Arkadiusz Jawien, MD||Speaker||Convatec and Schulke||Speaker|
|Mark Meissner, MD||Scientific Committee/Planner||Has nothing to disclose||N/A|
|Nick Morrison, MD, FACS, FACPh, RPhS||Scientific Committee/Planner||Medi; Merz; BTG; VenX||Speaker; Consultant; Principal Investigator; Scientific Advisory Board|
|Andrew Nicolaides, MS, FRCS, PhD (Hon)||Speaker||Servier International||Speaker|
|Michel Perrin, MD, FACPh||Speaker||Servier International||Consultant|
|Albert-Adrien Ramelet, MD||Speaker||Servier International; Boehringer Ingelheim||Speaker|
|Melvin Rosenblatt, MD, FACPh||Scientific Committee/Planner/Content Reviewer||Has nothing to disclose||N/A|
|Armando Schapira, MD||Speaker||NONE|
|Sherry Scovell, MD||Content Reviewer||Bolton Medical PPD||Data Safety and Monitoring Committee Member|
|Thomas Wakefield, MD||Scientific Committee/Planner||Has nothing to disclose||N/A|
|Steven Zimmet, MD, RVT, FACPh||Scientific Committee/Planner||Merz Aesthetics||Speaker|
The views and opinions expressed in this activity are those of the faculty and do not necessarily represent the views of the ACP. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting professional use of any of the information provided herein. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ACP Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Discussion of Off-Label Use
Although no longer required by the Accreditation Council for Continuing Medical Education (ACCME), ACP CME requests all faculty to inform learners of any products they will discuss that are off-label or investigational.
Reproduction of this material is not permitted without written permission from the copyright owner.
Review & Recertification
This course was reviewed and recertified for AMA PRA Category 1 CreditTM on March 25, 2015.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance